Orion Group Interim Report January–September 2023
INTERIM REPORT 1-9/2023
26 OCTOBER 2023 at 12:00 EEST
Orion Group Interim Report January–September 2023
- Net sales totalled EUR 868.5 (January–September 2022: 1,046.1) million
- Operating profit was EUR 182.0 (398.9) million
- Basic earnings per share were EUR 1.01 (2.26)
- Cash flow from operating activities per share was EUR 0.50 (3.05)
- EUR 30 million sales milestone from Nubeqa® recorded in Q3
- The outlook for 2023 is unchanged. Orion estimates that net sales in 2023 will be slightly higher than in 2022 without the EUR 228 million impact from the ODM-208 upfront payment (net sales in 2022 without the impact of the ODM-208 upfront payment were EUR 1,113 million). Operating profit is estimated to be slightly higher than in 2022 without the EUR 208 million net impact from the ODM-208 upfront payment and without the possible transfer of the insurance portfolio of Orion Pension Fund's B fund (operating profit in 2022 without the net impact of the ODM-208 upfront payment was EUR 232 million).
|7-9/23||7-9/22||Change %||1-9/23||1-9/22||Change %||1-12/22|
|Net sales, EUR million||301.1||491.8||-38.8%||868.5||1,046.1||-17.0%||1,340.6|
|EBITDA, EUR million||93.5||257.4||-63.7%||220.4||433.9||-49.2%||487.1|
|% of net sales||31.1%||52.3%||25.4%||41.5%||36.3%|
|Operating profit, EUR million||80.0||245.4||-67.4%||182.0||398.9||-54.4%||439.6|
|% of net sales||26.6%||49.9%||21.0%||38.1%||32.8%|
|Profit before taxes, EUR million||78.5||244.6||-67.9%||179.5||399.8||-55.1%||440.3|
|% of net sales||26.1%||49.7%||20.7%||38.2%||32.8%|
|Profit for the period, EUR million||61.4||194.5||-68.4%||141.6||317.9||-55.5%||349.5|
|% of net sales||20.4%||39.5%||16.3%||30.4%||26.1%|
|Research and development expenses, EUR million||27.2||35.7||-23.6%||90.3||95.2||-5.2%||133.2|
|% of net sales||9.1%||7.3%||10.4%||9.1%||9.9%|
|Capital expenditure, excluding acquired in business combinations, EUR million||31.0||18.8||+64.9%||66.7||49.3||+35.3%||109.6|
|% of net sales||10.3%||3.8%||7.7%||4.7%||8.2%|
|Acquired in business combination, net of cash, EUR million||1.3||0.1||82.4||-99.8%||82.0|
|Interest-bearing net liabilities, EUR million||122.5||-152.2||> 100 %||-118.7|
|Basic earnings per share, EUR million||0.44||1.38||-68.4%||1.01||2.26||-55.4%||2.49|
|Cash flow from operating activities per share, EUR||0.23||2.46||-90.5%||0.50||3.05||-83.6%||3.09|
|Equity ratio, %||61.8%||62.5%||60.9%|
|Return on capital employed (before taxes), %||22.9%||52.7%||45.1%|
|Return on equity (after taxes), %||21.6%||49.3%||42.2%|
|Average personnel during the period||3,587||3,451||+3.9%||3,472|
President and CEO Liisa Hurme:
Nubeqa® and Easyhaler® continue strong growth – Q3 was strong as expected
"In January–September 2023, our net sales were EUR 868.5 (1,046.1) million and the operating profit was EUR 182.0 (398.9) million. The decline in both reported net sales and operating profit is due to a significant EUR 228 million upfront payment recorded in the comparative period. Excluding this milestone and its net impact of EUR 208 million on result, our net sales increased slightly in January–September 2023 and operating profit was slightly down on last year but is improving as we have been expecting. The most important drivers for this positive development were the increase in Nubeqa® royalties, the increase in sales of the Easyhaler® product portfolio as well as EUR 30 million Nubeqa sales milestone that we have booked in Q3.
The negative impact of certain factors seen in the figures for the first half of 2023, such as Russia-related items, cost inflation and Nubeqa’s changed delivery price, started to ease in the third quarter of 2023, as expected. Overall, 2023 has progressed as anticipated, with the exception of lower than expected deliveries of entacapone products and some Animal Health products to our partners.
The decrease in net sales of the Generics and Consumer Health business division is explained by the decline in sales of Simdax® and dexmedetomidine products for human use, and closure of business in Russia. Overall, the rest of the portfolio performed well in challenging markets.
The development of the Branded Products business division was two-fold. Increased demand for dry-powder inhalers is the main reason for the growing sales and strong performance of the Easyhaler® product portfolio. The revenue from entacapone products declined due to lower deliveries to our partners, intensified competition, and declining prices in some markets. In addition, due to closure of business in Russia, the sales of Divina® Series declined. Thus, the total sales of the business division in January–September declined from the comparative period.
The Animal Health business division’s reported net sales increased because the comparative period’s net sales include the turnover of the animal health company Inovet, acquired in June 2022, only from July to September. However, in the third quarter the net sales of the business division declined from the comparative period due to continuous market softness and lower deliveries to our partners.
There has been one update in our clinical pipeline as we have initiated a Phase I clinical trial with ODM-212, a TEAD inhibitor aimed for the treatment of solid tumours with YAP/TEAD activation. Our other projects in the clinical phase are progressing as planned. We look forward to continuing all our R&D projects to develop new treatments for the benefit of patients with unmet need."
Outlook for 2023 (specified on 17 July 2023)
Orion estimates that net sales in 2023 will be slightly higher than in 2022 without the EUR 228 million impact from the ODM-208 upfront payment (net sales in 2022 without the impact of the ODM-208 upfront payment were EUR 1,113 million).
Operating profit is estimated to be slightly higher than in 2022 without the EUR 208 million net impact from the ODM-208 upfront payment and without the possible transfer of the insurance portfolio of Orion Pension Fund's B fund (operating profit in 2022 without the net impact of the ODM-208 upfront payment was EUR 232 million).
News Conference and Conference Call
A webcast and a conference call for analysts, investors and media representatives will be held on Thursday, 26 October 2023 at 13.30 EEST.
A link to the live webcast is available on Orion's website at www.orion.fi/en/investors. A recording of the event will be available on the website later the same day.
Confenrence call can be joined by registering through the following link:
Phone numbers and the conference ID to access the conference will be provided after the registration. In case you would like to ask a question during the conference, please dial *5 on your telephone keypad to enter the question queue.
Questions can also be presented in writing through the question form of the webcast.
|Financial Statement Release for 2023||Tuesday 13 February 2024|
|Annual General Meeting 2024||Planned to be held on 20 March 2024|
|Interim Report January–March 2024||Thursday 25 April 2024|
|Half-Year Financial Report January–June 2024||Thursday 8 August 2024|
|Interim Report January–September 2024||Tuesday 29 October 2024|
The Financial Statements and the Report of the Board of Directors for 2023 will be published on the Company's website at the latest in week 9/2024.
Espoo, October 26, 2023
Board of Directors of Orion Corporation
For additional information about the report:
Jari Karlson, CFO, tel. +358 50 966 2883
Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721 or +358 50 966 2721
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Buy-backs of shares in CoinShares International Limited29.11.2023 09:00:00 CET | Press release
29 November 2023 | SAINT HELIER, Jersey - As announced on 07 November 2023, the Board of Directors of CoinShares International Limited ("CoinShares" or the "Company") (Nasdaq Stockholm Market: CS; US OTCQX: CNSRF), Europe's leading alternative asset manager specialising in digital assets, resolved to extend a share buy-back program and repurchase shares on Nasdaq Stockholm Market during the period 07 November 2023, up to and including 30 May 2024 for total maximum amount of SEK 30 million in accordance with the authorisation from the Annual General Meeting on 31 May 2023. The Board of Directors’ resolution to implement the share buy-back program was made after the Board's review of the Company's capital structure and was implemented for the purposes of reducing the capital of the Company. The share buy-back program is carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) No 2016/1052 (the "Safe Harbour Regulatio
Deutsche Digital Assets Wins Pension Fund as Anchor Investor for DDA Crypto Select 10 ETP (SLCT)29.11.2023 09:00:00 CET | Press release
Institutional anchor investor for DDA Crypto Select 10 ETP (ISIN: DE000A3G3ZD0; WKN: A3G3ZD, Ticker: SLCT) The DDA Crypto Select 10 ETP reflects the MarketVector™ Digital Assets Max 10 VWAP Close Index (“MVDAMV”)With the ETP, investors are in a position to affordably gain exposure to a basket collection of (up to) the 10 most important crypto assetsThe ETP is 100% collateralized by coins held in an institutional custody solution FRANKFURT, Germany, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Deutsche Digital Assets GmbH has gained a renowned institutional anchor investor for the DDA Crypto Select 10 ETP (ISIN: DE000A3G3ZD0 | WKN: A3G3ZD), which was launched in June 2023. DDA prevailed against the competition in a selection process and was commissioned to design a crypto ETP that meets high quality standards and strict requirements of an institutional investor. After several months of preparation, this investment product can now be administered by a leading capital management company acting on be
Yara helps farmers combat the effects of climate change and improve nutrient use efficiency29.11.2023 08:40:00 CET | Press release
Global rise in temperatures has introduced a challenging reality for farmers worldwide. To meet the increasing demand for solutions to protect crops against climate change and optimize nutrient use efficiency, Yara is launching YaraAmplix™. A new brand that will expand the range of biostimulants. November 29th 2023 Milan: Climate change is putting many of the world’s most popular foods such as maize, tomato and wheat at risk of reduced crops. With the average global temperature on earth having already increased by over 1 degree Celsius in the last 100 years*1, agriculture is now experiencing more extreme weather than ever before with temperature increases being most severe on land. In response to farmers asking for solutions to increase crop resilience and nutrient use efficiency, Yara today announces the launch of YaraAmplix, a new brand of biostimulants, at the Biostimulant World Congress in Milan, Italy. “Extreme weather is destroying crops all over the world with drought, flooding
Sanoma Corporation - Managers' Transactions29.11.2023 08:30:00 CET | Press release
Sanoma Corporation, Managers’ Transactions, 29 November 2023 at 9:30 EET Sanoma Corporation - Managers' Transactions ___________________________________________ Person subject to the notification requirement Name: Holding Manutas Oy Position: Closely associated person (X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer Name: Herlin Anna Position: Member of the Board Issuer: Sanoma Oyj LEI: 743700XJC24THUPK0S03 Notification type: INITIAL NOTIFICATION Reference number: 44711/8/10 ____________________________________________ Transaction date: 2023-11-28 Venue: AQEU Instrument type: SHARE ISIN: FI0009007694 Nature of transaction: ACQUISITION Transaction details (1): Volume: 250 Unit price: 6.87 EUR (2): Volume: 32 Unit price: 6.9 EUR Aggregated transactions (2): Volume: 282 Volume weighted average price: 6.8734 EUR ____________________________________________ Transaction date: 2023-11-28 Venue: BEUP Instrument type: SHARE ISIN: FI0009007694 Nature of transaction:
Delårsrapport for 1. januar - 30. september 2023 for FirstFarms A/S29.11.2023 08:05:40 CET | pressemeddelelse
FirstFarms leverer tilfredstillende i udfordrende marked FirstFarms skaber fornuftige resultater på trods af høj inflation på omkostninger og stort pres på salgspriser. Omsætningsfremgang på 19% og fastholdelse af udmeldte forventninger til året. Bestyrelsen og direktionen i FirstFarms A/S har d.d. behandlet og godkendt det ureviderede delårsregnskab for perioden 1. januar - 30. september 2023. FirstFarms har i regnskabsperioden realiseret: Omsætning: 345 mDKK (2022: 291 mDKK)EBITDA: 79 mDKK (2022: 121 mDKK)EBIT: 42 mDKK (2022: 89 mDKK)Resultat før skat: 28 mDKK (2022: 77 mDKK) Produktion og resultatskabelse er tilfredsstillende med baggrund i de udfordrende forudsætninger FirstFarms har opereret under i årets første tre kvartaler. Resultatet er skabt som følge af en stabil, effektiv, cirkulær drift samt den risikospredning, der er et positivt og væsentligt særkende for koncernen. FirstFarms A/S fastholder derfor de udmeldte forventninger for 2023. Dog med et EBITDA i den nedre del af